Advertisement

Could Cassava Sciences Be a Millionaire-Maker Stock?

Could Cassava Sciences Be a Millionaire-Maker Stock?

Cassava Sciences (NASDAQ: SAVA) has been one of the top-performing biotech stocks of the past 12 months, rising over 3,210% in that time. Much of the hype surrounding Cassava lies in its flagship drug candidate, simufilam, which is currently under investigation to treat Alzheimer's disease. Large-cap biotech Biogen (NASDAQ: BIIB) recently advanced its own Alzheimer's drug, Aduhelm, past regulatory hurdles despite questionable efficacy data.